Abstract:Antiangiogenesis therapy has become a hot field in cancer research. Blood vessels of tumor carry specific markers that are usually related to angiogenesis. Study of these heterogeneous molecules in different tumor vessels may be beneficial for promoting antiangiogenic therapy. In this study, we established an in vitro co-culture model of human umbilical vein endothelial cells (HUVECs) and gastric adenocarcinoma cell line SGC7901, screened the peptides binding specifically to the HUVECs co-cultured with gastric cancer cells (Co-HUVECs) using phage display peptides library, and studied the affinity of these peptides to gastric cancer vascular endothelial cells. After four rounds of panning, there was an obvious enrichment for the phages specifically binding to the Co-HUVECs, and the output/input ratio of Co-HUVECs increased about 590-fold (from 0.95×10−7 to 561.25×10−7). Five phage clones (M6, M3, M9, IN12, IN11), which could strongly bind to Co-HUVECs instead of wild-type HUVECs, were characterized by ELISA. In vitro cellular binding assay showed that phage IN11 preferably bound to Co-HUVECs rather than control HUVECs, and the number of the phage IN11 recovered from Co-HUVECs was 5.7- and 16.9-folds, respectively, as much as those from control HUVECs and GES cells. Immunocytochemical and immunohistochemical staining confirmed that phage IN11 could specifically bind to Co-HUVECs as well as vascular endothelial cells in gastric cancer tissue sections. Competitive and inhibitory assay revealed the synthetic peptide GEBP11 (CTKNSYLMC) displayed on phage IN11 could competitively inhibit binding of the phage IN11 to Co-HUVECs. Immunofluorescence microscopy showed that the fluorescence-labeled peptide GEBP11 was located at the membrane and perinuclear cytoplasm of Co-HUVECs. Meanwhile, GEBP11 was found to be able to target the gastric cancer vascular endothelial cells. Therefore, GEBP11 may be a potential candidate for targeted drug delivery in antivascular therapy and diagnosis of gastric cancer.

In Vitro Screening of Ovarian Tumor Specific Peptides from a Phage Display Peptide Library

Screening and Identification of a Specific Binding Peptide to Ovarian Cancer Cells from a Phage-Displayed Peptide Library

Selection and identification of a specific peptide binding to ovarian cancer cells from a phage-displayed peptide library

Screening and identification of a specific peptide binding to breast cancer cells from a phage-displayed peptide library

Identifying Peptides That Specifically Bind to MDA-MB-468 Breast Cancer Cells*

Construction and identification of human ovarian carcinoma cDNA phage expression library

Targeting Osteosarcoma Vasculature with Peptide Obtained by Phage Display.

Advancements in ovarian cancer immunodiagnostics and therapeutics via phage display technology

Screening and identification of a specific peptide binding to cervical cancer cells from a phage-displayed peptide library

Her2 Targeting Peptides Screening And Applications In Tumor Imaging And Drug Delivery

Screening and Characterization of Inhibiting Peptides Binding to the Tumor Vascular Growth Factor Receptor

Selection and Characterization of a Peptide Specifically Targeting to Gastric Cancer Cell Line SGC-7901 Using Phage Display

A Multiplex Methylation-Specific Pcr Assay For Detection Of Early-Stage Ovarian Cancer Using Cell-Free Serum Dna

Screening and Identification of Vascular-Endothelial-cell-specific Binding Peptide in Gastric Cancer

Identification of Cell Membrane Protein Stress-Induced Phosphoprotein 1 As a Potential Ovarian Cancer Biomarker Using Aptamers Selected by Cell Systematic Evolution of Ligands by Exponential Enrichment

Identification of a peptide binding to cancer antigen Kita‐kyushu lung cancer antigen 1 from a phage‐display library

Screening and Identification of a Specific Peptide Binding to Hepatocellular Carcinoma Cells from a Phage Display Peptide Library

Tumor-Targeting Peptides Search Strategy for the Delivery of Therapeutic and Diagnostic Molecules to Tumor Cells

Screening of a specific peptide binding to esophageal squamous carcinoma cells from phage displayed peptide library.

[Screening of Breast Cancer Antigen from a Phage Display Random Peptide Library].

Phage display peptide probes for imaging early response to bevacizumab treatment